Uncategorized

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Published

4 hours ago

on

July 30, 2026

By

Temp User

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Related Topics:

Leave a Reply

Fierce Biotech4 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice
Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Endpoints News4 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized4 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play

Exit mobile version